Home LiteratureArticle Details
PMID: 1102616 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Group B streptococcus in a general hospital.

The Journal of infectious diseases ·Vol. 132 ·No. 5 ·1975-11-00 ·Pages 561-7

Anthony BF, Concepcion NF

Abstract

Eighty-six percent of 707 beta-hemolytic streptococci isolated in a general hospital and excluded by presumptive tests from groups A and D were identified serologically as group B. More than 70% of the group B isolates were from urine cultures, the female genital gract, or newborn infants. Types III and II were the most common group B serotypes from most sources. However, types Ia, Ib, and Ic were more commonly isolated from the respiratory tract than from other sites, and type III was responsible for most serious neonatal infections. All group B streptococci were sensitive in vitro to comparable levels of penicillin G, ampicillin, and cephalothin and were highly resistant to kanamycin. Seventy-two percent were resistant to tetracycline but only 1%-2% to erythromycin, clindamycin, and chloramphenicol. Despite consistent sensitivity to penicillin G, the minimal inhibitory concentrations were significantly higher for group B than for group A streptococci.

MeSH Terms
Cross Infection Drug Resistance, Microbial Female Humans Infant, Newborn Male Microbial Sensitivity Tests Pregnancy Streptococcal Infections Streptococcus agalactiae/isolation & purification
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Anthony B F
Concepcion N F
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
Published
1975-11-00
Pages
561-7
Language
English
Region
United States
NLM ID
0413675
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com